NASDAQ · VYNE
VYNE Therapeutics Inc.
$28.56$0.00 (0.0%)
VYNE Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.65% below the high.
Loading market information…
AMEX · AIM · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
AIM ImmunoTech Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.03% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
AIM ImmunoTech Inc.’s next earnings report is currently expected on Nov 16, 2026, with estimated earnings per share of -$0.09. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow AIM ImmunoTech Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 14, 2025 | -$5.00+37.5% vs estimate | $16.00K |
|---|
| Q4 2024 | Mar 27, 2025 | -$10.00-11.11% vs estimate | $45.00K-55.0% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | -$6.00-5,900.0% vs estimate | $35.00K+100.0% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$28.56$0.00 (0.0%)
VYNE Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.65% below the high.
$0.37-$0.02 (-5.95%)
Pasithea Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.06% below the high.
$0.44-$0.01 (-3.16%)
Ensysce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.36% below the high.
$4.15+$0.04 (+0.97%)
Quoin Pharmaceuticals, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 82.34% below the high.
$0.37-$0.01 (-1.55%)
Soligenix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.28% below the high.
$1.89-$0.24 (-11.27%)
Alaunos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.0% below the high.
$0.18-$0.00 (-2.67%)
KALA BIO, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.82% below the high.
$1.69+$0.04 (+2.42%)
Can-Fite BioPharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 86.37% below the high.
